Atropine

Atropine is a tropane alkaloid and anticholinergic medication used to treat certain types of nerve agent and pesticide poisonings as well as some types of slow heart rate, and to decrease saliva production during surgery.^[6] It is typically given intravenously or by injection into a muscle.^[6] Eye drops are also available which are used to treat uveitis and early amblyopia.^[7][8] The intravenous solution usually begins working within a minute and lasts half an hour to an hour.^[5] Large doses may be required to treat some poisonings.^[6]

Atropine

Clinical data
Trade names	Atropen, others
Other names	Daturin^[1]
AHFS/Drugs.com	Monograph
MedlinePlus	a682487
License data	US DailyMed: Atropine
Pregnancy category	AU: A
Routes of administration	By mouth, intravenous, intramuscular, rectal, ophthalmic
Drug class	antimuscarinic (anticholinergic)
ATC code	A03BA01 (WHO) S01FA01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)^[2] US: ℞-only^[3]^[4]
Pharmacokinetic data
Bioavailability	25%
Metabolism	≥50% hydrolysed to tropine and tropic acid
Onset of action	c. 1 minute^[5]
Elimination half-life	2 hours
Duration of action	30 to 60 min^[5]
Excretion	15–50% excreted unchanged in urine
Identifiers
IUPAC name (RS)-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenylpropanoate
CAS Number	51-55-8^Y
PubChem CID	174174
IUPHAR/BPS	320
DrugBank	DB00572^Y
ChemSpider	10194105^Y
UNII	7C0697DR9I
KEGG	D00113^Y
ChEBI	CHEBI:16684^Y
ChEMBL	ChEMBL517712
ECHA InfoCard	100.000.096
Chemical and physical data
Formula	C17H23NO3
Molar mass	289.375 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CN3[C@H]1CC[C@@H]3C[C@@H](C1)OC(=O)C(CO)c2ccccc2
InChI InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16?^Y Key:RKUNBYITZUJHSG-SPUOUPEWSA-N^Y
^NY (what is this?)  (verify)

Common side effects include dry mouth, abnormally large pupils, urinary retention, constipation, and a fast heart rate.^[6] It should generally not be used in people with closed-angle glaucoma.^[6] While there is no evidence that its use during pregnancy causes birth defects, this has not been well studied so sound clinical judgment should be used.^[9] It is likely safe during breastfeeding.^[9] It is an antimuscarinic (a type of anticholinergic) that works by inhibiting the parasympathetic nervous system.^[6]

Atropine occurs naturally in a number of plants of the nightshade family, including deadly nightshade (belladonna), Jimson weed, and mandrake.^[10] It was first isolated in 1833,^[11] It is on the World Health Organization's List of Essential Medicines.^[12] It is available as a generic medication.^[6][13][14]

Medical uses

 

An ampoule containing atropine injection 0.5mg/1mL

Eyes

Topical atropine is used as a cycloplegic, to temporarily paralyze the accommodation reflex, and as a mydriatic, to dilate the pupils.^[15] Atropine degrades slowly, typically wearing off in 7 to 14 days, so it is generally used as a therapeutic mydriatic, whereas tropicamide (a shorter-acting cholinergic antagonist) or phenylephrine (an α-adrenergic agonist) is preferred as an aid to ophthalmic examination.^[15]

In refractive and accommodative amblyopia, when occlusion is not appropriate sometimes atropine is given to induce blur in the good eye.^[16] Evidence suggests that atropine penalization is just as effective as occlusion in improving visual acuity.^[17][18]

Antimuscarinic topical medication is effective in slowing myopia progression in children; accommodation difficulties and papillae and follicles are possible side-effects.^[19] All doses of atropine appear similarly effective, while higher doses have greater side effects.^[20] The lower dose of 0.01% is thus generally recommended due to fewer side effects and potential less rebound worsening when the atropine is stopped.^[20][21]

Heart

Injections of atropine are used in the treatment of symptomatic or unstable bradycardia.

Atropine was previously included in international resuscitation guidelines for use in cardiac arrest associated with asystole and PEA, but was removed from these guidelines in 2010 due to a lack of evidence for its effectiveness.^[22] For symptomatic bradycardia, the usual dosage is 0.5 to 1 mg IV push; this may be repeated every 3 to 5 minutes, up to a total dose of 3 mg (maximum 0.04 mg/kg).^[23]

Atropine is also useful in treating second-degree heart block Mobitz type 1 (Wenckebach block), and also third-degree heart block with a high Purkinje or AV-nodal escape rhythm. It is usually not effective in second-degree heart block Mobitz type 2, and in third-degree heart block with a low Purkinje or ventricular escape rhythm.^{[citation needed]}

Atropine has also been used in an effort to prevent a low heart rate during intubation of children; however, evidence does not support this use.^[24]

Secretions

Atropine's actions on the parasympathetic nervous system inhibit salivary and mucus glands. The drug may also inhibit sweating via the sympathetic nervous system. This can be useful in treating hyperhidrosis, and can prevent the death rattle of dying patients. Even though atropine has not been officially indicated for either of these purposes by the FDA, it has been used by physicians for these purposes.^[25]

Poisonings

Atropine is not an actual antidote for organophosphate poisoning. However, by blocking the action of acetylcholine at muscarinic receptors, atropine also serves as a treatment for poisoning by organophosphate insecticides and nerve agents, such as tabun (GA), sarin (GB), soman (GD), and VX. Troops who are likely to be attacked with chemical weapons often carry autoinjectors with atropine and an oxime, for rapid injection into the muscles of the thigh. In a developed case of nerve-gas poisoning, maximum atropinization is desirable. Atropine is often used in conjunction with the oxime pralidoxime chloride.

Some of the nerve agents attack and destroy acetylcholinesterase by phosphorylation, so the action of acetylcholine becomes excessive and prolonged. Pralidoxime (2-PAM) can be effective against organophosphate poisoning because it can re-cleave this phosphorylation. Atropine can be used to reduce the effect of the poisoning by blocking muscarinic acetylcholine receptors, which would otherwise be overstimulated, by excessive acetylcholine accumulation.

Atropine or diphenhydramine can be used to treat muscarine intoxication.^{[medical citation needed]}

Atropine was added to cafeteria salt shakers in an attempt to poison the staff of Radio Free Europe during the Cold War.^[26][27]

Irinotecan induced diarrhea

Atropine has been observed to prevent or treat irinotecan induced acute diarrhea.^[28]

Side effects

Adverse reactions to atropine include ventricular fibrillation, supraventricular or ventricular tachycardia, dizziness, nausea, blurred vision, loss of balance, dilated pupils, photophobia, dry mouth and potentially extreme confusion, deliriant hallucinations, and excitation especially among the elderly. These latter effects are because atropine is able to cross the blood–brain barrier. Because of the hallucinogenic properties, some have used the drug recreationally, though this is potentially dangerous and often unpleasant.^{[medical citation needed]}

In overdoses, atropine is poisonous.^{[medical citation needed]} Atropine is sometimes added to potentially addictive drugs, particularly antidiarrhea opioid drugs such as diphenoxylate or difenoxin, wherein the secretion-reducing effects of the atropine can also aid the antidiarrhea effects.^{[medical citation needed]}

Although atropine treats bradycardia (slow heart rate) in emergency settings, it can cause paradoxical heart rate slowing when given at very low doses (i.e. <0.5 mg),^[29] presumably as a result of central action in the CNS.^[30] One proposed mechanism for atropine's paradoxical bradycardia effect at low doses involves blockade of inhibitory presynaptic muscarinic autoreceptors, thereby blocking a system that inhibits the parasympathetic response.^[31]

Atropine is incapacitating at doses of 10 to 20 mg per person. Its LD₅₀ is estimated to be 453 mg per person (by mouth) with a probit slope of 1.8.^[32] The antidote to atropine is physostigmine or pilocarpine.^{[medical citation needed]}

A common mnemonic used to describe the physiologic manifestations of atropine overdose is: "hot as a hare, blind as a bat, dry as a bone, red as a beet, and mad as a hatter".^[33] These associations reflect the specific changes of warm, dry skin from decreased sweating, blurry vision, decreased lacrimation, vasodilation, and central nervous system effects on muscarinic receptors, type 4 and 5. This set of symptoms is known as anticholinergic toxidrome, and may also be caused by other drugs with anticholinergic effects, such as hyoscine hydrobromide (scopolamine), diphenhydramine, phenothiazine antipsychotics and benztropine.^[34]

Contraindications

It is generally contraindicated in people with glaucoma, pyloric stenosis, or prostatic hypertrophy, except in doses ordinarily used for preanesthesia.^[3]

Chemistry

Atropine, a tropane alkaloid, is an enantiomeric mixture of d-hyoscyamine and l-hyoscyamine, with most of its physiological effects due to l-hyoscyamine. Its pharmacological effects are due to binding to muscarinic acetylcholine receptors. It is an antimuscarinic agent. Significant levels are achieved in the CNS within 30 minutes to 1 hour and disappears rapidly from the blood with a half-life of 2 hours. About 60% is excreted unchanged in the urine, most of the rest appears in urine as hydrolysis and conjugation products. Noratropine (24%), atropine-N-oxide (15%), tropine (2%) and tropic acid (3%) appear to be the major metabolites, while 50% of the administered dose is excreted as apparently unchanged atropine. No conjugates were detectable. Evidence that atropine is present as (+)-hyoscyamine was found, suggesting that stereoselective metabolism of atropine probably occurs.^[35] Effects on the iris and ciliary muscle may persist for longer than 72 hours.

The most common atropine compound used in medicine is atropine sulfate (monohydrate) (C
₁₇H
₂₃NO
₃)₂·H₂SO₄·H₂O, the full chemical name is 1α H, 5α H-Tropan-3-α ol (±)-tropate(ester), sulfate monohydrate.

Pharmacology

In general, atropine counters the "rest and digest" activity of glands regulated by the parasympathetic nervous system. This occurs because atropine is a competitive, reversible antagonist of the muscarinic acetylcholine receptors (acetylcholine being the main neurotransmitter used by the parasympathetic nervous system).

Atropine is a competitive antagonist of the muscarinic acetylcholine receptor types M1, M2, M3, M4 and M5.^[36] It is classified as an anticholinergic drug (parasympatholytic).

In cardiac uses, it works as a nonselective muscarinic acetylcholinergic antagonist, increasing firing of the sinoatrial node (SA) and conduction through the atrioventricular node (AV) of the heart, opposes the actions of the vagus nerve, blocks acetylcholine receptor sites, and decreases bronchial secretions.

In the eye, atropine induces mydriasis by blocking contraction of the circular pupillary sphincter muscle, which is normally stimulated by acetylcholine release, thereby allowing the radial iris dilator muscle to contract and dilate the pupil. Atropine induces cycloplegia by paralyzing the ciliary muscles, whose action inhibits accommodation to allow accurate refraction in children, helps to relieve pain associated with iridocyclitis, and treats ciliary block (malignant) glaucoma.

The vagus (parasympathetic) nerves that innervate the heart release acetylcholine (ACh) as their primary neurotransmitter. ACh binds to muscarinic receptors (M2) that are found principally on cells comprising the sinoatrial (SA) and atrioventricular (AV) nodes. Muscarinic receptors are coupled to the G_i subunit; therefore, vagal activation decreases cAMP. Gi-protein activation also leads to the activation of KACh channels that increase potassium efflux and hyperpolarizes the cells.

Increases in vagal activities to the SA node decreases the firing rate of the pacemaker cells by decreasing the slope of the pacemaker potential (phase 4 of the action potential); this decreases heart rate (negative chronotropy). The change in phase 4 slope results from alterations in potassium and calcium currents, as well as the slow-inward sodium current that is thought to be responsible for the pacemaker current (If). By hyperpolarizing the cells, vagal activation increases the cell's threshold for firing, which contributes to the reduction in the firing rate. Similar electrophysiological effects also occur at the AV node; however, in this tissue, these changes are manifested as a reduction in impulse conduction velocity through the AV node (negative dromotropy). In the resting state, there is a large degree of vagal tone on the heart, which is responsible for low resting heart rates.

There is also some vagal innervation of the atrial muscle, and to a much lesser extent, the ventricular muscle. Vagus activation, therefore, results in modest reductions in atrial contractility (inotropy) and even smaller decreases in ventricular contractility.

Muscarinic receptor antagonists bind to muscarinic receptors thereby preventing ACh from binding to and activating the receptor. By blocking the actions of ACh, muscarinic receptor antagonists very effectively block the effects of vagal nerve activity on the heart. By doing so, they increase heart rate and conduction velocity.

History

 

Atropa belladonna

The name atropine was coined in the 19th century, when pure extracts from the belladonna plant Atropa belladonna were first made.^[37] The medicinal use of preparations from plants in the nightshade family is much older however. Mandragora (mandrake) was described by Theophrastus in the fourth century B.C. for treatment of wounds, gout, and sleeplessness, and as a love potion. By the first century A.D. Dioscorides recognized wine of mandrake as an anaesthetic for treatment of pain or sleeplessness, to be given prior to surgery or cautery.^[33] The use of nightshade preparations for anesthesia, often in combination with opium, persisted throughout the Roman and Islamic Empires and continued in Europe until superseded in the 19th century by modern anesthetics.^{[citation needed]}

Atropine-rich extracts from the Egyptian henbane plant (another nightshade) were used by Cleopatra in the last century B.C. to dilate the pupils of her eyes, in the hope that she would appear more alluring. Likewise in the Renaissance, women used the juice of the berries of the nightshade Atropa belladonna to enlarge their pupils for cosmetic reasons. This practice resumed briefly in the late nineteenth and early twentieth century in Paris.^{[citation needed]}

The pharmacological study of belladonna extracts was begun by the German chemist Friedlieb Ferdinand Runge (1795–1867). In 1831, the German pharmacist Heinrich F. G. Mein (1799-1864)^[38] succeeded in preparing a pure crystalline form of the active substance, which was named atropine.^{[39] [40]} The substance was first synthesized by German chemist Richard Willstätter in 1901.^[41]

Natural sources

Atropine is found in many members of the family Solanaceae. The most commonly found sources are Atropa belladonna (the deadly nightshade), Datura innoxia, D. wrightii, D. metel, and D. stramonium. Other sources include members of the genera Brugmansia (angel's trumpets) and Hyoscyamus.^{[citation needed]}

Synthesis

Atropine can be synthesized by the reaction of tropine with tropic acid in the presence of hydrochloric acid.

Biosynthesis

The biosynthesis of atropine starting from l-phenylalanine first undergoes a transamination forming phenylpyruvic acid which is then reduced to phenyl-lactic acid.^[42] Coenzyme A then couples phenyl-lactic acid with tropine forming littorine, which then undergoes a radical rearrangement initiated with a P450 enzyme forming hyoscyamine aldehyde.^[42] A dehydrogenase then reduces the aldehyde to a primary alcohol making (−)-hyoscyamine, which upon racemization forms atropine.^[42]

Name

The species name "belladonna" ('beautiful woman' in Italian) comes from the original use of deadly nightshade to dilate the pupils of the eyes for cosmetic effect. Both atropine and the genus name for deadly nightshade derive from Atropos, one of the three Fates who, according to Greek mythology, chose how a person was to die.^[33]

See also

• Apoatropine
• Mark I Nerve Agent Antidote Kit

References

1. Rafinesque CS (1828). Medical Flora; Or, Manual of the Medical Botany of the United States of ... - Constantine Samuel Rafinesque - Internet Archive. Atkinson & Alexander. p. 148. Retrieved 2012-11-07.
2. "AusPAR: Atropine sulfate monohydrate". Therapeutic Goods Administration (TGA). 31 May 2022. from the original on 31 May 2022. Retrieved 12 June 2022.
3. "Atropine sulfate". dailymed.nlm.nih.gov. U.S. National Library of Medicine. from the original on 26 July 2020. Retrieved 30 October 2019.
4. "Atropine- atropine sulfate solution/ drops". DailyMed. 22 February 2022. from the original on 16 March 2022. Retrieved 16 March 2022.
5. Barash PG (2009). Clinical anesthesia (6th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 525. ISBN 9780781787635. from the original on 2015-11-24.
6. "Atropine". The American Society of Health-System Pharmacists. from the original on 2015-07-12. Retrieved Aug 13, 2015.
7. Hamilton RJ, Duffy AN, Stone D, Spencer A (2014). Tarascon pharmacopoeia (15 ed.). Jones & Bartlett Publishers. p. 386. ISBN 9781284056716. from the original on 2015-10-02.
8. "Amblyopia (Lazy Eye)". National Eye Institute. 2019-07-02. from the original on 2020-01-31. Retrieved 2020-01-31. Putting special eye drops in the stronger eye. A once-a-day drop of the drug atropine can temporarily blur near vision, which forces the brain to use the other eye. For some children, this treatment works as well as an eye patch, and some parents find it easier to use (for example, because young children may try to pull off eye patches).
9. "Atropine Pregnancy and Breastfeeding Warnings". from the original on 6 September 2015. Retrieved 14 August 2015.
10. Brust JC (2004). Neurological aspects of substance abuse (2 ed.). Philadelphia: Elsevier. p. 310. ISBN 9780750673136. from the original on 2015-10-02.
11. Ainsworth S (2014). Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. p. 94. ISBN 9781118819593. from the original on 2015-10-02.
12. World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
13. Hamilton RJ (2014). Tarascon pharmacopoeia (15 ed.). Jones & Bartlett Publishers. p. 386. ISBN 9781284056716. from the original on 2015-10-02.
14. "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. from the original on 29 June 2023. Retrieved 29 June 2023.
15. Yazdani N, Sadeghi R, Momeni-Moghaddam H, Zarifmahmoudi L, Ehsaei A (2018). "Comparison of cyclopentolate versus tropicamide cycloplegia: A systematic review and meta-analysis". Journal of Optometry. 11 (3): 135–143. doi:10.1016/j.optom.2017.09.001. PMC 6039578. PMID 29132914.
16. Georgievski Z, Koklanis K, Leone J (2008). "Fixation behavior in the treatment of amblyopia using atropine". Clinical and Experimental Ophthalmology. 36 (Suppl 2): A764–A765.
17. "A patch or eye drops are similarly effective for the treatment of "lazy eye" in children". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2019-12-05. doi:10.3310/signal-000849. S2CID 243130859.
18. Li T, Qureshi R, Taylor K (August 2019). "Conventional occlusion versus pharmacologic penalization for amblyopia". The Cochrane Database of Systematic Reviews. 8 (8): CD006460. doi:10.1002/14651858.CD006460.pub3. PMC 6713317. PMID 31461545.
19. Walline JJ, Lindsley KB, Vedula SS, Cotter SA, Mutti DO, Ng SM, Twelker JD (13 Jan 2020). "Interventions to slow progression of myopia in children". Cochrane Database Syst Rev. 1 (9): CD004916. doi:10.1002/14651858.CD004916.pub4. PMC 6984636. PMID 31930781.
20. Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L (June 2017). "Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis". JAMA Ophthalmology. 135 (6): 624–630. doi:10.1001/jamaophthalmol.2017.1091. PMC 5710262. PMID 28494063.
21. Fricke T, Hurairah H, Huang Y, Ho SM (2019). "Pharmacological interventions in myopia management". Community Eye Health. 32 (105): 21–22. PMC 6688412. PMID 31409953.
22. Field JM, Hazinski MF, Sayre MR, Chameides L, Schexnayder SM, Hemphill R, et al. (November 2010). "Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): S640-56. doi:10.1161/CIRCULATIONAHA.110.970889. PMID 20956217. S2CID 1031566.
23. * Bledsoe BE, Porter RS, Cherry RA (2004). "Ch. 3". Intermediate Emergency Care. Upper Saddle River, NJ: Pearson Prentice Hill. p. 260. ISBN 0-13-113607-0.
24. de Caen AR, Berg MD, Chameides L, Gooden CK, Hickey RW, Scott HF, et al. (November 2015). "Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 132 (18 Suppl 2): S526-42. doi:10.1161/cir.0000000000000266. PMC 6191296. PMID 26473000.
25. . eperc.mcw.edu. Archived from the original on 2014-04-14. Retrieved 2019-10-20.
26. The Battle Over Hearts and Minds A Cold War of Spies: Episode 4 |https://www.imdb.com/title/tt27484449/?ref_=ttep_ep4
27. "A Cold War of Spies | PBS America | UK".
28. Yumuk PF, Aydin SZ, Dane F, Gumus M, Ekenel M, Aliustaoglu M, et al. (November 2004). "The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients". International Journal of Colorectal Disease. 19 (6): 609–610. doi:10.1007/s00384-004-0613-5. PMID 15293062. S2CID 11784173.
29. "Atropine Drug Information". uptodate.com. from the original on 2014-02-20. Retrieved 2014-02-02.
30. * Rang HP, Dale MM, Ritter JM, Flower RJ (2007). "Ch. 10". Rang and Dale's Pharmacology. Elsevier Churchill Livingstone. p. 153. ISBN 978-0-443-06911-6.
31. Laurence B (2010). Goodman & Gilman's Pharmacological Basis of Therapeutics, 12th Edition. McGraw-Hill. ISBN 978-0-07-162442-8.
32. * Goodman E (2010). Ketchum J, Kirby R (eds.). Historical Contributions to the Human Toxicology of Atropine. Eximdyne. p. 120. ISBN 978-0-9677264-3-4.
33. Holzman RS (July 1998). "The legacy of Atropos, the fate who cut the thread of life". Anesthesiology. 89 (1): 241–9. doi:10.1097/00000542-199807000-00030. PMID 9667313. S2CID 28327277. Retrieved 2007-05-21. citing J. Arena, Poisoning: Toxicology-Symptoms-Treatments, 3rd edition. Springfield, Charles C. Thomas, 1974, p 345
34. Szajewski J (1995). "Acute anticholinergic syndrome". IPCS Intox Databank. from the original on 2 July 2007. Retrieved 2007-05-22.
35. Van der Meer MJ, Hundt HK, Müller FO (October 1986). "The metabolism of atropine in man". The Journal of Pharmacy and Pharmacology. 38 (10): 781–4. doi:10.1111/j.2042-7158.1986.tb04494.x. PMID 2879005. S2CID 27306334.
36. Rang HP, Dale MM, Ritter JM, Moore P (2003). Pharmacology. Elsevier. p. 139. ISBN 978-0-443-07145-4.
37. Goodman and Gilman's Pharmacological Basis of Therapeutics, q.v. "Muscarinic receptor antagonists - History", p. 163 of the 2001 edition.
38. . ostfriesischelandschaft.de (in German). Archived from the original on 2013-05-11. Retrieved 2019-10-20.{{cite web}}: CS1 maint: unfit URL (link)
39. Heinrich Friedrich Georg Mein (1833). "Ueber die Darstellung des Atropins in weissen Kristallen" [On the preparation of atropine as white crystals]. Annalen der Pharmacie (in German). Vol. 6 (1 ed.). pp. 67–72. from the original on 2016-05-15. Retrieved 2016-01-05.
40. Atropine was also independently isolated in 1833 by Geiger and Hesse:
    • Geiger, Hesse (1833). "Darstellung des Atropins" [Preparation of atropine]. Annalen der Pharmacie (in German). Vol. 5. pp. 43–81. from the original on 2016-05-14. Retrieved 2016-01-05.
    • Geiger, Hesse (1833). "Fortgesetzte Versuche über Atropin" [Continued experiments on atropine]. Annalen der Pharmacie (in German). Vol. 6. pp. 44–65. from the original on 2016-06-10. Retrieved 2016-01-05.
41. See:
    • Willstätter R (1901). "Synthese des Tropidins" [Synthesis of tropidine]. Berichte der Deutschen Chemischen Gesellschaft zu Berlin (in German). 34: 129–144. doi:10.1002/cber.19010340124. from the original on 2013-03-01.
    • Willstätter R (1901). "Umwandlung von Tropidin in Tropin" [Conversion of tropidine into tropine]. Berichte der Deutschen Chemischen Gesellschaft zu Berlin (in German). 34 (2): 3163–3165. doi:10.1002/cber.190103402289. from the original on 2013-01-26.
42. Dewick PM (9 March 2009). Medicinal Natural Products: A Biosynthetic Approach (3rd ed.). Chichester: A John Wiley & Sons. ISBN 978-0-470-74167-2.

External links

•   Media related to Atropine at Wikimedia Commons
• "Atropine". Drug Information Portal. U.S. National Library of Medicine.
• "Atropine sulfate". Drug Information Portal. U.S. National Library of Medicine.